Scientific Advisory Board
Leonard Zon, MD
Co-founder, Scholar Rock®
Grousbeck Professor of Pediatric Medicine at Harvard Medical School, Director of the Stem Cell Program at Children's Hospital Boston, and HHMI Investigator

For more information:
Zon Lab

Barry Coller, MD
Physician in Chief, Vice President for Medical Affairs, and the David Rockefeller Professor, The Rockefeller University

For more information:
Coller Lab

Jeffrey S. Flier, MD
Higginson Professor of Physiology and Medicine and Harvard University Distinguished Service Professor
Former Dean of Harvard Medical School
Scott L. Friedman, MD
Professor of Medicine, Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai Hospital, New York

For more information:
Friedman Lab

Michael Gilman, PhD
CEO, Arrakis Therapeutics
CEO, Obsidian Therapeutics

Michael Gilman, Ph.D. is currently Chairman and Chief Executive Officer for Arrakis Therapeutics, Inc., a role he has served in since 2016, and Chief Executive Officer and Director for Obsidian Therapeutics, Inc., a role he has served in since 2016. Previously, from 2014 to 2016 Dr. Gilman was Founder and Chief Executive Officer of Padlock Therapeutics, Inc. Prior to Padlock, Dr. Gilman served as Senior Vice President, Early-Stage Pipeline, at Biogen Idec Inc. from 2012 to 2013. He joined Biogen Idec Inc. in 2012 following its acquisition of Stromedix, Inc., where he was Founder and Chief Executive Officer. Prior to founding Stromedix in 2006, from 1999 to 2005, Dr Gilman served in a variety of capacities, most recently as Executive Vice President, Research at Biogen Idec. From 1994 to 1999, Dr. Gilman was at ARIAD Pharmaceuticals, Inc., where he was Executive Vice President and Chief Scientific Officer. From 1986 to 1994, Dr. Gilman was on the scientific staff of Cold Spring Harbor Laboratory in New York. He also serves on the Board of Directors of X4 Pharmaceuticals, Inc. and the Scientific Advisory Board of FutuRx, an Israeli biotech accelerator. Dr. Gilman was a postdoctoral fellow with Dr. Robert Weinberg at the Whitehead Institute. He holds a Ph.D. in Biochemistry from University of California, Berkeley, and an S.B. in Life Sciences from Massachusetts Institute of Technology.

Joan Massagué, PhD
Director, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center

For more information:
Massagué Lab

Daniel Rifkin, PhD
Charles Aden Poindexter Professor of Medicine, New York University Langone Medical Center

For more information:
Rifkin Lab

Lynn Sakai, PhD
Professor of Biochemistry & Molecular Biology, Oregon Health & Science University; Senior Investigator,Portland Shriners Research Center

For more information:
Sakai Lab

Akshay Vaishnaw, MD, PhD
President, Research & Development, Alnylam Pharmaceuticals, Inc.

Dr. Vaishnaw joined Alnylam Pharmaceuticals in 2006, and currently serves as President, Research and Development.  Prior to Alnylam, he held various positions of increasing responsibility in clinical research and business development at Biogen, Inc., mostly recently Senior Director, Translational Medicine.  Dr. Vaishnaw received a B.S. from University College Cardiff, U.K., an M.D. from the University of Wales College of Medicine, U.K., and a Ph.D. in molecular immunology from the University of London, U.K.  He is a Fellow of the Royal College of Physicians, U.K. Dr. Vaishnaw also serves on the Board of Directors for Editas Medicine, Inc.

Shelia M. Violette, PhD
Entrepreneur in Residence, Atlas Venture
Dr. Violette was previously Vice President of Tissue Injury and Fibrosis Research at Biogen where she spearheaded a team of scientists conducting discovery research and developing translational approaches to advance programs into clinical development. From 2008 to 2012, Dr. Violette was Vice President of Research at Stromedix and led all research activities supporting the development of the anti-v6 antibody, STX-100. Dr. Violette has more than 20 years of industry experience advancing programs from early research to clinical development. She has provided strategic and operational leadership to multi-disciplinary teams of scientists and authored more than 80 manuscripts and patents. Dr. Violette has directed research and led therapeutic programs at several biotechnology companies including Repligen, Ariad, Stromedix and Biogen. She is currently an Entrepreneur in Residence at Atlas Venture, Cambridge, MA. Dr. Violette received her Ph.D. in Pharmacology from Yale University and carried out her post-doctoral training with Frank Ruddle in the Department of Biology at Yale University.
“Scholar Rock” is a registered trademark of Scholar Rock, Inc.  |  © 2019 Scholar Rock All Rights Reserved.
Back to Top

The site you are about to visit is maintained by another organization, which is solely responsible for its content. As we cannot control the content or privacy practices of any third-party websites, we encourage you to read the privacy policy of every website you visit.

Continue   Cancel